Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in the netherlands

Journal of Pediatric Gastroenterology and Nutrition

Volumn 39, Issue 1, 2004, Pages 46-52

  de Ridder, Lissy ^a   Escher, Johanna C ^a   Bouquet, Jan ^b   Schweizer, Joachim J ^b   Rings, Edmond H H M ^c   Tolboom, Jules J M ^c   Houwen, Roderick H J ^d   Norbruis, Obbe F ^d   Derkx, Bert H F ^d   Taminiau, Jan A J M ^d  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adverse effects; Crohn disease; Fistula; Inflammatory bowel disease; Infliximab; Pediatric

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CROHN DISEASE; FEMALE; HUMAN; IMMUNOLOGY; INTESTINE FISTULA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NETHERLANDS; PHYSIOLOGY; RECTOVAGINAL FISTULA; RECTUM FISTULA; TIME; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; COHORT STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTESTINAL FISTULA; MALE; NETHERLANDS; RECTAL FISTULA; RECTOVAGINAL FISTULA; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14644440656     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/00005176-200407000-00010     Document Type: Article

References (26)

1. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
2. Lichtenstein GR. Approach to steroid-dependent and steroid-refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2001;33:S27-35.
3. Breese EJ, Michie CA, Nicholls S, et al. Tumor necrosis factor (-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-66.
4. Derkx B, Taminiau J, Radema S, et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993;342:173-4.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
6. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
7. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;761-9.
8. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
9. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N Engl J Med 1997;337:1029-35.
10. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:542-9.
11. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
12. Hyams J, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
13. Serrano M-S, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
14. Stephens MC, Shepansky MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
15. Cezard J-P, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36:632-6.
16. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 2003;36:90-5.
17. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a Pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
18. Escher JC, Stoof TJ, van Deventer SJ, et al. Successful treatment of metastatic Crohn's disease with infliximab. J Pediatr Gastroenterol Nutr 2002;34:420-3.
19. Otley A, Loonen H, Parekh N, et al. Assessing activity of pediatric Crohn's disease: which index to use?Gastroenterology 1999;116:527-31.
20. Griffiths AM, Nguyen P, Smith, C et al. Growth and clinical course of children with Crohn's disease. Gut 1993;34:939-43.
21. Bodegraven AA, Sloots CEJ, Felt-Bersma RJF, et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002;45:39-46.
22. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002;97:2350-6.
23. Nikolaus S, Raedler A, Kühbacher T, et al. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
24. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
25. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002;97:1408-14.
26. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97:2962-2.